Roche Pharmaceutical Development and Sales Overview

Tecentriq (atezolizumab, RG7446) Anti-PD-L1 cancer immunotherapy - renal cell cancer Indication Phase/study # of patients Design Primary endpoint Status CT Identifier " Advanced renal cell carcinoma (RCC) after immune checkpoint inhibitor treatment ARM A: Tecentriq plus cabozantinib ARM B: Cabozantinib Progression-free survival and overall survival " FPI Q3 2020 Recruitment completed Q4 2021 1In collaboration with Exelixis PD-L1-Programmed cell death-ligand 1; DFS=Disease-free survival Phase III Contact-031 N=500 NCT04338269 Roche 71 Oncology

View entire presentation